The Life Sciences Sector plan was released today (16 July 2025)
Similar Posts
The MHRA and the global flu vaccine: How the UK is helping shape the world’s flu vaccine
Ensuring the seasonal flu vaccine is ready, safe and effective involves months of international planning, testing and collaboration
Five festive mistakes you didn’t know you were making: MHRA urges the public to be merry, not risky – don’t mix medicines with alcohol
This holiday season, the MHRA is highlighting one of the most overlooked winter health risks: combining medicines with alcohol.
Field Safety Notices: 02-06 February 2026
List of Field Safety Notices: 02-06 February 2026
MHRA updates guidance for semaglutide prescribers and patients
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
Decision: Advertising Investigations: July 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.